Show simple item record

dc.creatorBalfour-Lynn, I. M.
dc.creatorKing, J. A.
dc.date.accessioned2020-08-24T23:23:16Z
dc.date.available2020-08-24T23:23:16Z
dc.date.created2020-05
dc.identifier.issn1526-0542spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S1526054220300816?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12183
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherPaediatric Respiratory Reviewsspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectFibrosis quísticaspa
dc.titleCFTR modulator therapies – Effect on life expectancy in people with cystic fibrosisspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.subject.keywordCystic fibrosisspa
dc.subject.keywordMortalityspa
dc.subject.keywordPrognosisspa
dc.subject.keywordCFTR modulatorsspa
dc.identifier.doihttps://doi.org/10.1016/j.prrv.2020.05.002spa
dc.description.abstractenglishCFTR modulators have dramatically changed the clinical course of CF in those fortunate enough to receive them. Inevitably, randomised controlled trials during the development of these drugs are too short to use mortality as an outcome. Evidence for their effect on life expectancy are best gained from real world registry studies specifically looking at mortality, but these are only available for ivacaftor to date. Therefore, indirect evidence must be obtained by looking at outcomes known to affect mortality and seeing the effect of these drugs on those outcomes.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record